In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio, with a price target of $8.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Inmune Bio’s strategic position and potential for growth. Despite reporting a net loss in the second quarter of 2025, the company maintains a solid cash position expected to support operations into 2027. The recent leadership change, with David Moss stepping in as CEO, may bring fresh perspectives to the company’s strategic direction.
Inmune Bio’s pipeline shows promise, particularly with its CORDStrom cell therapy program, which has shown positive results in treating recessive dystrophic epidermolysis bullosa (RDEB). The program’s potential for expedited review due to its Orphan Drug and Rare Pediatric Disease Designations adds to its attractiveness. Additionally, the company’s ongoing efforts to partner with the FDA and seek collaborations for further development of its Alzheimer’s treatment, despite mixed trial results, indicate a proactive approach to overcoming challenges and capitalizing on therapeutic signals.